Table 5.

Long-term survival rates in the present study compared with those reported with immunochemotherapy regimens

Reference	Study	ClinicalTrials.gov identifier	Regimen	N	10-y OS (95% CI), %
Present study	SAKK 35/03	NCT00227695	4× R weekly + short R maintenance	82	77.9 (66.3-85.9)
			4× R weekly + long R maintenance	83	79.0 (67.9-86.7)
Morschhauser et al, 201321	FIT	NCT00185393	Chemotherapy ± R*	202	81 (NR) at 8 y
			Chemotherapy ± R* +90Y-ibritumomab	207	84 (NR) at 8 y
Bachy et al, 201318	FL2000	NCT00136552	CHVP + interferon	183	69.8 (63.1-76.6) at 8 y
			R-CHVP + interferon	175	78.6 (72.5-84.7) at 8 y
Rummel et al, 201723	StiL NHL1	NCT00991211	R-bendamustine	261	71 (NR)
			R-CHOP	253	66 (NR)
Nastoupil et al, 201722	MDACC	NCT00577993	FND, followed by R and IFN	78	76 (67-86)
			R-FND followed by IFN	80	73 (64-84)
Luminari et al, 201820	FOLL05	NCT00774826	R-CVP	178	85 (77-91) at 8 y
			R-CHOP	178	83 (75-89) at 8 y
			R-FM	178	79 (71-85) at 8 y
Shadman et al, 201824	SWOG-S0016	NCT00006721	R-CHOP	267	81 (75.9-85.4)
			CHOP + 131I-tositumomab	264	75 (69.3-80.2)
Bachy et al, 201919	PRIMA	NCT00140582	R-CHOP/R-CVP/R-FCM	513	79.9 (NR)
			R-CHOP/R-CVP/R-FCM + R maintenance	505	80.1 (NR)

CHOP, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine, and prednisolone; CHVP, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), etoposide, and prednisolone; CVP, cyclophosphamide, vincristine, and prednisone; IFN, interferon; NR, not reported; R, rituximab; R-FCM, rituximab, fludarabine, cyclophosphamide, and mitoxantrone; R-FM, rituximab, fludarabine, and mitoxantrone; R-FND, rituximab, fludarabine, mitoxantrone, and dexamethasone; ±, with or without.

^*First-line therapy with chlorambucil, CVP, CHOP, CHOP-like, fludarabine combinations, with or without rituximab.